Seqens eBook - 36

Creating Opportunities Means
Looking Where Others Are Not
To date, Seqens has three manufacturing sites in Europe (Couterne,
Limay, Aramon) and one in Canada (St Jean-sur-Richelieu - Québec)
involved in polymers synthesis. Our strong expertise in polymer
development and manufacturing enables us to address different
markets including lubricants, electronics, cosmetics, photovoltaic
and pharma. Two of these sites are listed cGMP (Aramon, Limay) and
gather together up to 250 employees who work intensively on active
pharmaceutical ingredients (APIs) manufacturing and polymers
synthesis for pharma applications including drug delivery and
medical device. Our capabilities enable us to work from kg to ton scale,
and also to carry out a wide range of polymerization technologies
including Ring Opening Polymerisation (R.O.P.), controlled radical
polymerisation (RAFT) and condensation polymerisation.

of CNRS at Institut Galien Paris Sud) with the Seqens Prize 2018 for his
outstanding achievement in this field.

Expansorb® Application
PLA are used in medical device applications especially in the
preparation of suture or orthopaedic devices. For instance, Inion
HEXALON is using PLA to generate biodegradable screw to secure
fixation and maintain the stability of bone-tendon-bone grafts.
Gradually the screw loses strength during 18-36 weeks and totally
resorbed in two to four years.
Seqens' Expansorb® porfolio is the pillar for the implementation of
new biodegradable polymers and continues to expand through the

Biopolymers as Excipient

development of several block polymers by our customers: PLA-PEG,

Aramon cGMP production site is notably specialized in functional
polymers production for drug delivery purpose.
Within this unit, we have developed a portfolio of biodegradable
Poly (D,L-lactic acid) (PLA) and poly (D,L-lacticdelivery co-glycolic
acid) (PLGA) polymers well known under Expansorb® brand. These
polyester polymers are approved as excipients in drug delivery
systems (implants, parenteral) of injectable APIs for the controlled
and slow release (weeks to months) of the final drug product. Indeed
excipients are playing a key role in solubility and bioavailability of a
final drug as well as in targeting biodistribution.
In other words, these polymers are typically used to reduce multiple
injections, toxicity level and to achieve the desired therapeutic
effect. A number of well-known medicines on the market have been
using PLGA controlled release since 1988, including Sandostatin
LAR (octreotide ), Decapeptyl® (triptorelin ), Zoladex (goserelin )
and Lupron Depot (leuprolide acetate). We leverage our 18 years
of expertise in this field and can now provide our customers up to
50 references to support them in tackling formulation challenges
encountered at early stage of drug development. In 2016, we entered
into an agreement with Merck to expand its excipients portfolio.

Innovation in Biopolymers Field
To date, Merck is the exclusive, global distributor of the Expansorb®
line of biocompatible and biodegradable polymers. It is noteworthy
to mention that polymers as carriers for drug delivery systems
continuously attracted interest of a numerous scientists who provide
an extensive breakthrough in this field. The French Academy of
Sciences has recently awarded Dr Julien NICOLAS (research director
Pharmaceutical Outsourcing |

PLGA-PEG , diblock, triblock polymers as well as a polycaprolactone
(PCL) which will be available soon in the market.

Seqens Solutions for Pharma Needs
Other solutions are offered by Seqens to address pharma needs.
For instance, we manufacture a PEKK (Poly-Ether-Ketone-Ketone)
polymer, a material that exhibits more resistance and is useful for
long-term implantable human devices with quite unlimited life cycle
such as orthopedics, neurological, dental, spinal and cardiovascular
implants but also in PEKK-based 3D-printed bones. Our capabilities
and our expertise also enable us to manufacture resins under GMP
aiming at purifying protein like insulin. Our polymers teams are
currently working on the development of semi-conductive polymerbased sensors for biomedical applications and target especially skin
biosensor system, which play nowadays a large and growing role in
medical diagnostics and patient monitoring.
In addition, we deliver to our clients the best-in-class custom
polymer services as well as full regulatory support (IMPD, DMF
filing) in their project.

Karine SALIM, PhD
Global Category Manager
Drug Delivery & Medical Materials
Custom Synthesis & Pharma Chemicals
36

| pharmoutsourcing.com



http://www.pharmoutsourcing.com

Seqens eBook

Table of Contents for the Digital Edition of Seqens eBook

Contents
Seqens eBook - 1
Seqens eBook - Contents
Seqens eBook - 3
Seqens eBook - 4
Seqens eBook - 5
Seqens eBook - 6
Seqens eBook - 7
Seqens eBook - 8
Seqens eBook - 9
Seqens eBook - 10
Seqens eBook - 11
Seqens eBook - 12
Seqens eBook - 13
Seqens eBook - 14
Seqens eBook - 15
Seqens eBook - 16
Seqens eBook - 17
Seqens eBook - 18
Seqens eBook - 19
Seqens eBook - 20
Seqens eBook - 21
Seqens eBook - 22
Seqens eBook - 23
Seqens eBook - 24
Seqens eBook - 25
Seqens eBook - 26
Seqens eBook - 27
Seqens eBook - 28
Seqens eBook - 29
Seqens eBook - 30
Seqens eBook - 31
Seqens eBook - 32
Seqens eBook - 33
Seqens eBook - 34
Seqens eBook - 35
Seqens eBook - 36
https://www.nxtbookmedia.com